Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Inclusion Criteria:

- Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke -
Alzheimer's Disease Related Disorders Association(NINCDS-ADRDA) and Diagnostic and
Statistical Manual of Mental Disorders-Forth Edition, Text Revision (DSM-IV-TR)
criteria

- Mini-Mental State Exam (MMSE) Score between 20 & 26 (inclusive)

- CSF consistent with AD pathology

- Screening brain MRI - normal - commensurate with age or demonstrate atrophy
consistent with AD diagnosis (dx); reveal no more than mild white matter disease; up
to 2 lacunar infarcts acceptable except in anterior thalamus, genu of internal
capsule or basal forebrain; reveal no cortical infarcts; reveal no more than 4
microbleeds; reveal no focal asymmetric lobar atrophy or other findings suggesting
primary cause of dementia is attributed to a cause other than AD; reveal no
macrohemorrhages (>10 mm)

- Subjects must have reliable study partners

- Men and Women of Non Child Bearing Potentia (WONCBP), ages 50-90 years

Exclusion Criteria:

- Subjects with any other medical condition other than mild AD that could explain
subjects' memory or cognitive deficits

- Subjects diagnosed with moderate or severe AD per DSM-IV criteria

- Subjects with a history (hx) of stroke

- Subjects with a hx of GI illnesses

- Subjects with Vitamin B12 or folate deficiency

- Subjects with any unstable cardiovascular (CV), pulmonary, Gastrointestinal (GI) or
hepatic disease within 30 days prior to screening

- Subjects with active liver dx or history of hepatic intolerance

- Subjects with a Geriatric Depression Scale score of ≥ 6 at screening

- Subjects treated for or have had a diagnosis of schizophrenia

- Subjects treated for or have had a diagnosis of bipolar disease within 3 years prior
to screening

- Subjects with a history of generalized peripheral neuropathy